Augmentation of ADCC activity according to FcR polymorphisms in patients with gastric cancer who receive monoclonal antibody therapy

接受单克隆抗体治疗的胃癌患者中 FcR 多态性导致 ADCC 活性增强

• 批准号: 23591934
• 负责人: YOSHINO Shigefumi
• 金额: $ 3.16万
• 依托单位: Yamaguchi University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591934/
• 关键词: 胃癌; 大腸癌; ADCC活性; 抗体医薬; Fc受容体; 遺伝子多型; レンチナン

Monoclonal antibodies are widely used for patients with gastric or colorectal cancer. These drugs have direct effect on the tumor cells, however modulation of the immune response could be another important mechanism. Antibody dependent cellular cytotoxicity (ADCC) mediated through the receptor (FcR) of the antibodies carried by immune cells plays an important role in the antitumor effect of the antibody. In this study, we confirmed that both monoclonal antibodies of trastuzumab and cetuximab had ADCC activity, however immunomodulator lentinan showed no augmentation of ADCC. Genetic features of FcR polymorphisms may be associated with the outcome of cancer patients treated with monoclonal antibodies.

单克隆抗体广泛用于胃癌或结直肠癌患者。这些药物对肿瘤细胞有直接作用，但免疫反应的调节可能是另一个重要机制。通过免疫细胞携带的抗体受体（FcR）介导的抗体依赖性细胞毒性（ADCC）在抗体的抗肿瘤作用中发挥着重要作用。在这项研究中，我们证实曲妥珠单抗和西妥昔单抗的单克隆抗体都具有 ADCC 活性，但免疫调节剂香菇多糖没有显示 ADCC 增强作用。 FcR 多态性的遗传特征可能与单克隆抗体治疗癌症患者的结果有关。